Realities and Challenges of Pharmaceutical Development

Elaine Hamm, PhD CEO Ascend BioVentures


We have all heard the statistics...



Table 1: Probabilities of Phase Failure by Disease Group

The table shows the average probability of failing each phase of the FDA drug development process, broken down by disease groups. These failure rates are from data from 2006-2015, and are taken from Thomas et. al. (2016).

	Probability of Failing Phase Conditional on Reaching It				
Disease Group	Phase 1	Phase 2	Phase 3	NDA/BLA Approval Phase	Overall Probabilit of Failure
Hematology	27%	43%	25%	16%	74%
Infectious Disease	31%	57%	27%	11%	81%
Ophthalmology	15%	55%	42%	23%	83%
Other Disease Groups	33%	60%	30%	12%	84%
Metabolic	39%	55%	29%	22%	85%
Gastroenterology	24%	64%	39%	8%	85%
Allergy	32%	68%	29%	6%	85%
Endocrine	41%	60%	35%	14%	87%
Respiratory	35%	71%	29%	5%	87%
Urology	43%	67%	29%	14%	89%
Autoimmune/immunology	34%	68%	38%	14%	89%
Neurology	41%	70%	43%	17%	92%
Cardiovascular	41%	76%	45%	16%	93%
Psychiatry	46%	76%	44%	12%	94%
Oncology	37%	75%	60%	18%	95%



Source: Pharmaceutical Research and Manufacturers of America

What is it REALLY like to be the little guy?

The good

- Pivot, move quickly, innovation encouraged
- State economic incentives
- Cheaper
- Virtual labs are possible

The bad

- Isolated
- Inexperienced investors

The ugly

- Funding (equity or grant). Lack thereof or just plain slow.
- Inexperienced management
- Lack of industry guidance (or even interaction)
- Discrimination

Time is everything




FUNDING TIMELINES

EXPERIMENTAL TIMELINES

DEAL TIMELINES

Reality of timing for funding

Grants



* Assuming no government shutdown

Ō

Experimental timing: Example of Animal experiment

In-house chemistry, vivarium: 5 weeks

- 1 day of planning
- 1 week to get protocol approved
- 1 week to get animals
- 1 week to acclimate
- 1 week to do the experiment
- 1 week analysis

- Outsourcing animal work (small company)? Add 2-4 weeks
- Outsourcing animal work (large company)? Add 3-6 weeks (horror story: 7 months!)
- Outsourcing chemistry?
 Add 1 month

Synereca Pharmaceuticals

Great early stage data and momentum

- Potent, low toxicity
- Experienced management, great advisors
- Finalist for CARB-X, high scores on CDMRP grant
- Capital from local investors

However...

- Too early for startup
- Funding purgatory (too early, too late)
- Differing feedback ("if you just did...")

Pamlico BioPharma

Good early stage data

- Highly specific, low chance for resistance
- Experienced management
- Capital from local investors
- Sublicense with diagnostic company

However...

- Too specific
- Challenging patent protection
- The business case was too hard
- Science and the COGS were challenging

Are these challenges all startups have?

Yes, to some degree

• Money, inexperience, and resources are always a challenge

However:

- Type of market and potential ROI helps
- Other startup companies:

Diabetes Company- Clear industry milestones. Big market. Grant funded. Failed but failed fast with guidance from potential partners.

Hearing Loss Company- High market interest, orphan opportunities, not very crowded. Grant funded, investor funded, multiple deals on the table.

NASH Company- High market interest, clear interest and milestones from potential partners and investors.

Changing the Outlook

Earlier help from pharma

- Need large pharma to invest, guide, mentor
- How do we incentivize?

New business/partner models

• Accelerators, collaborative research agreements, industry-academia-startup advisory committees



Experience

• Startups are usually young, hungry innovators...but they need guidance on company management, drug development, deal making, etc.

Support

- For younger entrepreneurs (and minorities and women)
- For early stage innovation

Questions?

Elaine Hamm, PhD – ehamm@ascendbioventures.com